


FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty.  
Dkt. No.

C: M#

Client Ref:

051501-0276397

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Inventor(s): Ware

Appln. No.: 09/549,096

Filing Date: April 12, 2000

Date: April 19, 2004

Page 1 of 1

Examiner: P. Huynh

Group Art Unit: 1644

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.):

Examiner's Initials*			English Abstract		Translation Readily Available	
			Enclosed	No	Enclosed	No
PNH	AR	Puglielli et al.; Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway; Nature Medicine, Vol. 5, No. 12; December 1999; p. 1370-1374				
	BR	Inada et al.; Biomedical and biotechnological applications of PEG- and PM-modified proteins; Trends in Biotechnology, Vol. 13; March 1995; p. 86-91				
	CR	Mckay et al.; Both the Lymphotoxin and Tumor Necrosis Factor Pathways Are Involved in Experimental Murine Models of Colitis; Gastroenterology, Vol. 115; 1998; p. 1464-1475				
	DR	Francis et al.; PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques; International Journal of Hematology, Vol. 68; 1998; p. 1-18				
	ER	Burnham; Polymers for delivering peptides and proteins; Am J Hosp Pharm, Vol. 51; January 15, 1994; p. 210-229				
	FR	Mumtaz et al.; Conjugation of proteins and enzymes with hydrophilic polymers and their applications; Indian Journal of Biochemistry & Biophysics, Vol. 28, October & December 1991; p. 346-351				
	GR					
	HR					
	IR					
	JR					
	KR					
	LR					

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.